Pulmatrix Announces FDA Acceptance Of IND Application For PUR3100 To Treat Acute Migraine
Benzinga Newsdesk 3 years ago
BiotechNewsFDAGeneral
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine